The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
 
Charles S. Fuchs
Leadership - CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health
Consulting or Advisory Role - Agios; Agios; Agios; Agios; Bain Capital; Bain Capital; Bain Capital; Bain Capital; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Dicerna; Dicerna; Dicerna; Dicerna; Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; KEW; KEW; KEW; KEW; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merrimack; Merrimack; Merrimack; Merrimack; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Unum Therapeutics; Unum Therapeutics; Unum Therapeutics; Unum Therapeutics
 
Javad Shahidi
Employment - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo
 
Lijoy Mathew
Employment - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo
 
Amy Qin
Employment - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - amgen (Inst); amgen (Inst); amgen (Inst); amgen (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst)